Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy, Tolerability, and Safety of Palbociclib Combined With an Aromatase Inhibitor in Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Locally Advanced Breast Cancer

NCT04047758 is registered in ClinicalTrials.gov with Shengjing Hospital as lead sponsor.

NCT NCT04047758
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04047758 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy, Tolerability, and Safety of Palbociclib Combined With an Aromatase Inhibitor in Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Locally Advanced Breast Cancer
Lead sponsor
Shengjing Hospital
Phase
Phase 3
Overall status
Unknown status
Start date
September 1, 2019
Completion date
September 30, 2022
Enrollment
420 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer